Pulse Biosciences (NASDAQ:PLSE) Trading Up 7.6% – Should You Buy?

Pulse Biosciences, Inc. (NASDAQ:PLSE)’s share price was up 7.6% during mid-day trading on Tuesday . The company traded as high as $16.34 and last traded at $16.34. Approximately 33,479 shares changed hands during trading, a decline of 83% from the average daily volume of 200,741 shares. The stock had previously closed at $15.19.

Analyst Ratings Changes

Separately, StockNews.com raised Pulse Biosciences to a “sell” rating in a report on Friday, September 20th.

Pulse Biosciences Stock Performance

The stock’s 50 day moving average price is $17.33 and its two-hundred day moving average price is $14.53.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same period in the prior year, the firm earned ($0.19) earnings per share.

Institutional Trading of Pulse Biosciences

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its position in Pulse Biosciences by 28.8% during the 1st quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock worth $7,379,000 after acquiring an additional 189,227 shares in the last quarter. Cetera Advisors LLC acquired a new position in Pulse Biosciences in the first quarter valued at approximately $109,000. BNP Paribas Financial Markets raised its position in shares of Pulse Biosciences by 63.6% during the 1st quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company’s stock worth $66,000 after purchasing an additional 2,952 shares during the period. Price T Rowe Associates Inc. MD acquired a new position in shares of Pulse Biosciences during the first quarter valued at $88,000. Finally, Quest Partners LLC bought a new stake in Pulse Biosciences in the 2nd quarter valued at about $91,000. Hedge funds and other institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.